These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

659 related items for PubMed ID: 19996015

  • 1. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD.
    Circulation; 2009 Dec 22; 120(25):2586-96. PubMed ID: 19996015
    [Abstract] [Full Text] [Related]

  • 2. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ, Kottke-Marchant K, Gorman RT.
    Platelets; 2008 Mar 22; 19(2):104-10. PubMed ID: 17852773
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
    Marcucci R, Paniccia R, Antonucci E, Gori AM, Fedi S, Giglioli C, Valente S, Prisco D, Abbate R, Gensini GF.
    Am J Cardiol; 2006 Nov 01; 98(9):1156-9. PubMed ID: 17056317
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US.
    Circulation; 2007 Jun 26; 115(25):3156-64. PubMed ID: 17562955
    [Abstract] [Full Text] [Related]

  • 6. Letter by Violi et al regarding article, "Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization".
    Violi F, Pignatelli P, Basili S.
    Circulation; 2010 Aug 17; 122(7):e429; author reply e430. PubMed ID: 20713906
    [No Abstract] [Full Text] [Related]

  • 7. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM.
    Platelets; 2005 Aug 17; 16(5):269-80. PubMed ID: 16011977
    [Abstract] [Full Text] [Related]

  • 8. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
    Christiaens L, Ragot S, Mergy J, Allal J, Macchi L.
    Blood Coagul Fibrinolysis; 2008 Apr 17; 19(3):235-9. PubMed ID: 18388505
    [Abstract] [Full Text] [Related]

  • 9. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.
    Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG.
    Eur Heart J; 2007 Jul 17; 28(14):1702-8. PubMed ID: 17569678
    [Abstract] [Full Text] [Related]

  • 10. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study.
    Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerico A, Biagini A.
    Thromb Res; 2006 Jul 17; 118(4):487-93. PubMed ID: 16343603
    [Abstract] [Full Text] [Related]

  • 11. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R.
    Am J Cardiol; 2007 Jun 01; 99(11):1518-22. PubMed ID: 17531573
    [Abstract] [Full Text] [Related]

  • 12. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
    Małek ŁA, Spiewak M, Filipiak KJ, Grabowski M, Szpotańska M, Rosiak M, Główczyńska R, Imiela T, Huczek Z, Opolski G.
    Kardiol Pol; 2007 Jan 01; 65(1):40-5; discussion 46. PubMed ID: 17295159
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O'connor CM.
    Am Heart J; 2003 Oct 01; 146(4):713-20. PubMed ID: 14564328
    [Abstract] [Full Text] [Related]

  • 15. Factors responsible for "aspirin resistance" - can we identify them?
    Postuła M, Tarchalska-Kryńska B, Filipiak KJ, Kosior D, Serafin A, Huczek Z, Opolski G.
    Kardiol Pol; 2010 Apr 01; 68(4):403-11; discussion 412-3. PubMed ID: 20425699
    [Abstract] [Full Text] [Related]

  • 16. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population.
    Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, Bray PF, Becker LC.
    Am J Cardiol; 2006 Sep 15; 98(6):774-9. PubMed ID: 16950183
    [Abstract] [Full Text] [Related]

  • 17. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
    Würtz M, Grove EL, Kristensen SD, Hvas AM.
    Heart; 2010 Mar 15; 96(5):368-71. PubMed ID: 19910291
    [Abstract] [Full Text] [Related]

  • 18. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM, Claeys MJ, Haine S, Miljoen H, Bosmans JM, Vertessen F, Kluppels K, Van der Planken M, Vrints CJ.
    Am Heart J; 2010 Mar 15; 159(3):434-8. PubMed ID: 20211306
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
    Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF.
    Circulation; 2009 Jan 20; 119(2):237-42. PubMed ID: 19118249
    [Abstract] [Full Text] [Related]

  • 20. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
    Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF.
    Thromb Haemost; 2010 Aug 20; 104(2):279-86. PubMed ID: 20508896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.